Guidance for Pfizer Inc. (PFE)
Period | Range | Estimate | Revenue Range | Revenue Estimate | Target | Details |
---|---|---|---|---|---|---|
2023 | $1.45 – $1.65 | $1.50 | $58.00B – 61.00B | $55.37B | = Maintained | Details |
2023 | $3.25 – $3.45 | $4.44 | $67.00B – 71.00B | $74.13B | Lowered | Details |
2023 | $3.25 – $3.45 | $3.36 | $67.00B – 71.00B | $68.67B | = Maintained | Details |
2023 | $3.25 – $3.45 | $3.01 | $67.00B – 70.00B | $61.00B | = Maintained | Details |
2022 | $6.35 – $6.55 | $6.65 | $98.00B – 102.00B | $106.50B | Lowered | Details |
2022 | $6.25 – $6.45 | $7.15 | $98.00B – 102.00B | $107.90B | Lowered | Details |
2022 | $6.30 – $6.45 | $6.38 | $99.50B – 102.00B | $99.60B | = Maintained | Details |
2022 | $6.30 – $6.45 | $6.62 | $98.00B – 102.00B | $103.00B | = Maintained | Details |
2021 | $3.10 – $3.20 | $3.19 | $59.40B – 61.40B | $56.72B | Raised | Details |
2021 | $3.55 – $3.65 | $3.36 | $70.50B – 72.50B | $62.99B | Raised | Details |
2021 | $4.13 – $4.18 | N/A | $81.00B – 82.00B | N/A | Raised | Details |
2021 | $3.95 – $4.05 | $3.70 | $78.00B – 80.00B | $72.78B | = Maintained | Details |
2020 | $2.82 – $2.92 | $2.90 | $48.50B – 50.50B | $49.52B | = Maintained | Details |
2020 | $2.82 – $2.92 | $2.86 | $48.50B – 50.50B | $49.33B | = Maintained | Details |
2020 | $2.85 – $2.95 | $2.88 | $48.60B – 50.60B | $49.10B | Raised | Details |
2020 | $2.88 – $2.93 | $2.90 | $48.80B – 49.50B | $49.34B | = Maintained | Details |
2019 | $2.83 – $2.93 | $2.89 | N/A | N/A | = Maintained | Details |
2019 | $2.82 – $2.92 | $3.04 | $52.00B – 54.00B | $54.36B | = Maintained | Details |
2019 | $2.76 – $2.86 | $2.91 | $50.50B – 52.50B | $53.28B | Lowered | Details |
2019 | $2.94 – $3.00 | $2.82 | $51.20B – 52.20B | $51.32B | Raised | Details |
2018 | $2.95 – $3.05 | $2.95 | $53.00B – 55.00B | $54.30B | = Maintained | Details |
2018 | $2.98 – $3.02 | $2.99 | N/A | N/A | = Maintained | Details |
Q2 2018 | N/A | N/A | N/A | N/A | = Maintained | Details |
Q1 2018 | N/A | N/A | N/A | N/A | = Maintained | Details |
2017 | $2.50 – $2.60 | N/A | $52.00B – 54.00B | N/A | = Maintained | Details |
2017 | $2.50 – $2.60 | $2.55 | $52.00B – 54.00B | $53.15B | = Maintained | Details |
2017 | $2.54 – $2.60 | $2.55 | $52.00B – 54.00B | N/A | = Maintained | Details |
Q4 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
2016 | $2.20 – $2.30 | $2.36 | $49.00B – 51.00B | $52.50B | = Maintained | Details |
2016 | $2.38 – $2.48 | $2.30 | $51.00B – 53.00B | $51.24B | Raised | Details |
2015 | $1.95 – $2.05 | $2.07 | $44.00M – 46.00M | $45.94M | Lowered | Details |
2015 | $2.00 – $2.10 | $2.18 | $44.50B – 46.50B | $47.56B | = Maintained | Details |
2014 | $2.20 – $2.30 | $2.28 | $49.20B – 51.20B | $49.74B | = Maintained | Details |
2014 | $2.23 – $2.27 | $2.24 | $48.70B – 49.70B | $49.50B | = Maintained | Details |
2013 | $2.20 – $2.30 | $2.29 | $56.20B – 58.20B | $57.55B | = Maintained | Details |
2013 | $2.15 – $2.20 | $2.16 | $50.80B – 51.80B | $51.45B | = Maintained | Details |
2013 | $2.14 – $2.24 | $2.28 | $55.30M – 57.30M | $57.30M | = Maintained | Details |
2012 | $2.14 – $2.17 | $2.21 | N/A | N/A | = Maintained | Details |
2011 | $2.16 – $2.26 | $2.30 | $66.00B – 68.00B | $66.80B | = Maintained | Details |